View more job listings or post a job
University of California, Davis TOXICOLOGY GROUP LEADER (LABORATORY RESCHEARCH SUPERVISOR 2)                    
Xencor Scientist, Immuno-Oncology
Xencor Research Associate 3, Immuno-Oncology
Genentech Senior Scientist, Small Molecule Analytical Chemistry
Horizon Therapeutics Director, Nonclinical Safety (Toxicology) R0004281
Roivant Sciences Director, Translational Sciences and Immunology
Horizon Therapeutics Senior Clinical Pharmacologist
Post a job


[Free Online Seminar] Fighting pancreatic cancer: current treatments, pipeline landscape, and PanCAN's drug development projects

Speakers: Anne-Marie Duliege, MD, Chief Medical Officer, Pancreatic Cancer Network (PanCAN)
Date: 2021-12-07- 12/5/2021
Time: 11:30-13:30 Pacific Time
Registration fee: (USD):
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration deadline:2021-12-06  (it will close sooner if the seating cap is reached)

About the Topic

Drug development in metastatic pancreatic ductal adenocarcinoma (PDAC) has been disappointing with a 5 year survival rate of only 10% despite considerable effort.  Precision Promise is a transformative, adaptive registration clinical trial platform that attempts to correct this by continuously and rapidly evaluating novel therapeutic options while nurturing enhanced cooperation among groups representing patient advocacy, pharmaceuticals, translational/clinical academia, and the FDA. This patient-centric study represents a fundamental shift that can substantially accelerate drug development for PDAC . PanCAN is also leading translational research by facilitating genetic testing of patients with pancreatic cancer (“Know Your Tumor” program), and has recently launched an Early Detection Initiative (EDI) in patients with recent onset diabetes.

About the Speakers

As Chief Medical Officer for the Pancreatic Cancer Action Network, Anne-Marie Duliege, MD, is responsible for the strategic direction and operational oversight for the organization’s clinical initiatives, including PanCAN’s Precision Promise℠ clinical trial.

From 2004 to 2013, Dr. Duliege was VP then CMO and Head of Research and Clinical Development at Affymax. Under her leadership, her team completed an extensive development program and obtained FDA approval of the company’s lead product for anemia in dialysis patients. Prior to that, Dr. Duliege worked at Chiron and Genentech on various programs including an HIV vaccine and treatment. Prior to her career in the biopharmaceutical industry, Dr. Duliege was an epidemiologist with the National Institute of Science and Medical Research in Paris.

2022-12-07, [Free Online Symposium] Gene Therapy: Discovery, Development and Regulatory Perspectives
2022-12-15, [Free Online Symposium] Success Stories and Lessons Learned from Recent FDA Approvals: INQOVI (decitabine+cedazuridine) by Astex - Otsuka for the treatment of myelodysplastic syndromes (MDS)
2023-02-06, [Free Online Symposium] Promising Biotech Startups
2023-02-08, [Free Online Workshop] New Product Launch: What Does it Take to Bring a New Product to Market?
©Pharmaceutical & BioScience Society, International; Last Modified: 12/3/2022; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Hypha Discovery Synthesis, purification & NMR characterization of phase 1 and 2 drug metabolites at mg-g scale with COAs. New gut metabolites service.
Programmable Drug Delivery Evaluate drug efficacy in animal models in a clinically relevant manner with a Programmable Refillable and implantable pump. 3Rs and group housed.
Programmable Drug Delivery PK/PD models and the limitations of traditional dosing methods. Methods & benefits of implantable microinfusion pumps in both rats & mice.
Submit a Text Ad